ENB Therapeutics
Business Services · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
430 E 29th St Fl 14, New York, New York,...Phone Number
(212) 792-2317Website
www.enbpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About ENB Therapeutics
ENB Therapeutics specializes in developing innovative therapies to overcome immunotherapy resistance in cancer treatment. Their unique mechanisms target the tumor microenvironment to enhance the body's immune response against drug-resistant cancers. The company focuses on creating small molecules that convert cold tumors into hot tumors and promote the formation of intratumoral tertiary lymphoid organs. Their therapies have demonstrated preclinical efficacy across various cancer types, including melanoma, glioblastoma, and ovarian cancer.Explore more
ENB Therapeutics Org Chart
SJ
President & Co-Founder & Chief Scientific Off...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ENB Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if ENB Therapeutics has recently received funding, and reach out quickly before it becomes old news!
ENB Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when ENB Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if ENB Therapeutics is spiking on competitors!
Earning: See what the market has to say on ENB Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once ENB Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at ENB Therapeutics
Click to see if ENB Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at ENB Therapeutics
Find more new buyers
Compare Similar Companies to ENB Therapeutics
Compare insights from companies similar to ENB Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ENB Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ENB Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ENB Therapeutics.
ENB Therapeutics Tech Stack
A closer look at the technologies used by ENB Therapeutics
ENB Therapeutics News & Media
ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023
NEW YORK--(BUSINESS WIRE)--ENB Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced top-line results from the dual combination arm of the Phase 1b ENBOLDEN-101 study, evaluating ENB-003 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced refractory cancers. The results show encouraging objective responses, disease control and extended progression-free survival in patients with platinum reENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Solid Tumors Refractory to Standard of Care at the Immuno-oncology Summit 2023
NEW YORK--(BUSINESS WIRE)--ENB Therapeutics, Inc., a biotechnology company pioneering a new and differentiated class of therapeutics targeting the endothelin B receptor (ETBR) inhibitor, today announced that the company has completed enrollment of its international Phase 1 ENBOLDEN-101 trial investigating the safety and efficacy of lead product ENB-003 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. The Phase ½a study is a multicenter, open-label study conducted in the
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ENB Therapeutics
Sign Up For FreeTo access detailed company insights
ENB Therapeutics specializes in developing innovative therapies to overcome immunotherapy resistance in cancer treatment. Their unique mechanisms target the tumor microenvironment to enhance the body's immune response against drug-resistant cancers. The company focuses on creating small molecules that convert cold tumors into hot tumors and promote... Read More
